Chlordecone is an endocrine disrupter with hormonal estrogenic properties in vitro and in vivo. Exposure to chlordecone has been associated with an increased risk of developing prostate cancer. Variants in the genes associated with estrogen and / or androgen metabolism may modulate the effect of endocrine disrupters on prostate cancer. To study the interactions between exposure to chlordecone and functional polymorphisms of 5 genes coding for estrogen (CYP17, CYP19, COMT, CYP1B1, UGT1A1) related to the risk of developing prostate cancer.
INTRODUCTION AND OBJECTIVES:
Chlordecone is an endocrine disrupter with hormonal estrogenic properties in vitro and in vivo. Exposure to chlordecone has been associated with an increased risk of developing prostate cancer. Variants in the genes associated with estrogen and / or androgen metabolism may modulate the effect of endocrine disrupters on prostate cancer. To study the interactions between exposure to chlordecone and functional polymorphisms of 5 genes coding for estrogen (CYP17, CYP19, COMT, CYP1B1, UGT1A1) related to the risk of developing prostate cancer.
METHODS: This monocentric study included 498 patients with prostate cancer (incident cases) were compared to 565 control subjects from the general population in Guadeloupe. Genetic polymorphisms were analyzed by the determination of point mutations by the SNaPshot procedure (CYP17, CYP1B1, COMT) or by the identification of the number of repeats by length analysis of the PCR products (CYP19, UGT1A1). Subjects were ranked by quartiles according to the distribution of exposure in controls.Interactions were estimated by logistic regression, adjusted to potential confounders, stratified by alleles. Interactions with p <0.2 were taken into account.
RESULTS: Subjects classified in the 4th quartile of exposure and carrying a number of repetitions (TTTA) n> 7 for CYP19 have a significant increased risk of prostate cancer (Odds Ratio (OR): 3.2; at 95% (95% CI): 1.5 -6.9). The genotype CC of CYP1B1 for patient with high exposure to chlordecone is associated with a significant increased risk of prostate cancer (Odds Ratio (OR): 2.6; at 95% (95% CI): 1.3 -5.1). The variant rs60271534 of CYP19 is characterized by a high number of repeats and gives the aromatase an increased catalytic power. The functional variant rs1056836 of the gene coding for CYP1B1 is associated with a lower catalytic activity.
CONCLUSIONS: The association between exposure to chlordecone and the risk of prostate cancer appears to be modulated by the presence of the functional variant of CYP1B1 and CYP19. The role of environmental estrogens in interaction with endogenous estrogens might modulate the risk of prostate cancer. METHODS: Four cell lines were used: LNCaP, a human prostate cancer cell line that exhibits androgen-dependent proliferation; C4-2, an ENZ-sensitive CRPC cell line; C4-2AT6, an ENZ-resistant CRPC cell line which had been established by incubating C4-2 in androgen ablation conditions; and 22Rv1, a AR-V7 positive CRPC cell line. We analyzed genetic copy number variants in LNCaP, C4-2 and C4-2AT6 cells by array-CGH, and found BCL-6 as a potential therapeutic target gene.
RESULTS: At first, we examined the efficacy of ENZ for LNCaP and C4-2AT6 cells. In cell viability assay, C4-2AT6 had significant ENZ resistance. To investigate ENZ resistance mechanism, we analyzed genetic copy number variants in LNCaP, C4-2 and C4-2AT6 cells. Array-CGH array demonstrated that BCL-6 expression was higher in the order C4-2AT6 > C4-2 > LNCaP. We validated these results using quantitative PCR and western blotting. The mRNA and protein expression level of BCL-6 was also higher in C4-2AT6 cells. We evaluated the cytotoxic effect of a BCL-6 inhibitor, 79-6, on C4-2AT6 cells. Relative cell viability when treated with 10 mM 79-6 was 65.7 AE 0.8%. Western blotting revealed that 79-6 promoted p53 expression and PARP cleavage in C4-2AT6 cells. We also examined the effect of BCL-6 inhibition by gene knockdown with siRNA. Knockdown of BCL-6 significantly reduces the cell viability of C4-2AT6 cells (78.4 AE 1.4%). We examined the synergistic effect of ENZ and 79-6 on C4-2AT6 cells. The relative cell viability when treated with 1 mM ENZ and 10 mM 79-6 was 43.5 AE 2.1%. Because AR-V7 was focused as mechanism of ENZ resistance, we tested anti-tumor effect of 79-6 for AR-V7 positive CRPC cells. 22Rv1 had AR-V7 expression while LNCaP and C4-2AT6 did not (Fig. a) . WST assay demonstrated 79-6 inhibited 22Rv1 proliferation (78.3 AE 1.9%). Western blotting demonstrated AR-V expression was down-regulated after 79-6 administration. 79-6 also sensitized 22Rv1 for ENZ in WST assay like C4-2AT6 (Fig. b) .
CONCLUSIONS: BCL-6 inhibition was able to overcome AR variants positive CRPC.
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MP64-03 MIR-361-5P MODULATES METABOLISM AND AUTOPHAGY VIA THE SP1-MEDIATED REGULATION OF PKM2 IN PROSTATE CANCER
Tao Tao*, Zhixin Ling, Jun Xiao, Hefei, China, People's Republic of INTRODUCTION AND OBJECTIVES: The dysregulation of metabolism and autophagy contributes to the progression of PCa. The transcription factor specificity protein 1 (Sp1) is implicated in the regulation of metabolism and autophagy. We confirmed that Sp1 is overexpressed in castration-resistant prostate cancer (CRPC) cells. However, the roles of Sp1 in PCa metabolism and autophagy remain unclear. This study aims to determine whether or not the signalling pathway of Sp1 serves key functions in PCa development.
METHODS: We retrieved the GSE35988 dataset from Gene Expression Omnibus (GEO) database to reinvestigate Sp1 expression and its role in PCa. Transfection efficiency of si-SP1 was determined by Western blot analysis. The effects of sh-SP1 on prostate cancer cells e850 THE JOURNAL OF UROLOGY â Vol. 199, No. 4S, Supplement, Sunday, May 20, 2018 
